127 related articles for article (PubMed ID: 24151657)
41. [Peptide-based cancer vaccine therapy for prostate cancer, bladder cancer, and malignant glioma].
Yamada A
Nihon Rinsho; 2011 Sep; 69(9):1657-61. PubMed ID: 21922770
[TBL] [Abstract][Full Text] [Related]
42. Summary of presentations from the 11th targeted therapies for lung cancer meeting: immunotherapy and vaccines for treatment of lung cancer.
Ujhazy P; Carbone D
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1815-7. PubMed ID: 22005542
[No Abstract] [Full Text] [Related]
43. [Personalized peptide vaccine for cancer treatment; now and its future].
Waki K; Yamada A
Nihon Rinsho; 2017 Feb; 75(2):251-256. PubMed ID: 30562860
[TBL] [Abstract][Full Text] [Related]
44. [CTL precursor-oriented peptide vaccine therapy for malignant glioma].
Yajima N; Yamanaka R; Tanaka R; Shigemori M; Mine T; Itoh K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():582-7. PubMed ID: 16201585
[No Abstract] [Full Text] [Related]
45. HLA typing demands for peptide-based anti-cancer vaccine.
Nagorsen D; Thiel E
Cancer Immunol Immunother; 2008 Dec; 57(12):1903-10. PubMed ID: 18317754
[TBL] [Abstract][Full Text] [Related]
46. Epidermal growth factor vaccine in non-small-cell lung cancer.
Gonzalez Marinello GM; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2012 Apr; 12(4):439-45. PubMed ID: 22500681
[TBL] [Abstract][Full Text] [Related]
47. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
48. Immune therapies for lung cancer.
Gettinger S
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S394-6. PubMed ID: 23160331
[No Abstract] [Full Text] [Related]
49. Peptide-based vaccination for colorectal cancer.
Tsuruma T; Hata F; Furuhata T; Ohmura T; Katsuramaki T; Yamaguchi K; Kimura Y; Torigoe T; Sato N; Hirata K
Expert Opin Biol Ther; 2005 Jun; 5(6):799-807. PubMed ID: 15952910
[TBL] [Abstract][Full Text] [Related]
50. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
[TBL] [Abstract][Full Text] [Related]
51. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
Raez LE; Santos ES; Mudad R; Podack ER
Expert Rev Anticancer Ther; 2005 Aug; 5(4):635-44. PubMed ID: 16111464
[TBL] [Abstract][Full Text] [Related]
52. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
53. [New strategy for treatment of patients with pancreatic cancer--clinical significance of peptide vaccine for pancreatic cancer].
Yamaue H
Nihon Shokakibyo Gakkai Zasshi; 2011 Oct; 108(10):1639-45. PubMed ID: 21971138
[No Abstract] [Full Text] [Related]
54. [I. History of Immunotherapy and Cancer Vaccine for Lung Cancer].
Suzuki H; Takagi H; Owada Y; Watanabe Y; Inoue T; Fukuhara M; Yamaura T; Muto S; Okabe N; Hasegawa T; Shio Y
Gan To Kagaku Ryoho; 2017 Aug; 44(8):646-649. PubMed ID: 28860434
[No Abstract] [Full Text] [Related]
55. Overcoming doubts and other obstacles in the development of effective peptide-based therapeutic vaccines against cancer.
Cho HI; Celis E
Expert Rev Vaccines; 2010 Apr; 9(4):343-5. PubMed ID: 20370542
[No Abstract] [Full Text] [Related]
56. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
57. Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396232
[No Abstract] [Full Text] [Related]
58. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
Suekane S; Yutani S; Yamada A; Sasada T; Matsueda S; Takamori S; Toh U; Kawano K; Yoshiyama K; Sakamoto S; Sugawara S; Komatsu N; Yamada T; Naito M; Terasaki M; Mine T; Itoh K; Shichijo S; Noguchi M
Int J Oncol; 2020 Jun; 56(6):1479-1489. PubMed ID: 32236612
[TBL] [Abstract][Full Text] [Related]
59. Immunologic therapies for gastrointestinal cancers.
Levy B; Deeken JF; Holt G; Marshall JL
Clin Colorectal Cancer; 2005 May; 5(1):37-49. PubMed ID: 15929805
[TBL] [Abstract][Full Text] [Related]
60. The quest for an efficacious lung cancer vaccine.
Murray N
Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S4-5. PubMed ID: 18540528
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
